Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OC5T
|
|||
| Drug Name |
ANX005
|
|||
| Indication | Neurodegenerative disorder [ICD-11: 8A20-8A23] | Phase 1 | [1] | |
| Company |
Annexon Biosciences South San Francisco, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement C1s component (C1S) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Pertussis | ||||
| Staphylococcus aureus infection | ||||
| Systemic lupus erythematosus | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| Complement Activation, Classical Pathway | ||||
| Human Complement System | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.